Opening a new facility,
"Our customers needed to manufacture their products on a significantly larger scale, and we were able to invest in an expansion of our existing production facilities to support their requirements. We were very pleased to be able to deliver this expansion in just over four months in order to meet the needs of present and potential new clients", comments Anders Wikström, EVP Operations of
The availability of raw materials for mRNA vaccine production has been a major bottleneck as the lipids that were needed for new LNP (Lipid Nano Particles formulations used in mRNA vaccines) were not previously available on the scale needed to produce billions of doses of vaccine globally. The rapid development of a scalable and reliable route into commercial production of these lipids has been made possible with the aid of
The newly opened production facility will enable
"This initiative is an example of how
This information was submitted for publication, through the agency of the contact persons set out above, at
Contact persons:
Tomas Blomquist, CEO
Tel: 0705 23 01 63, tomas.blomquist@biotage.com
About Biotage
Biotage is a
Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner -
Our customers span a broad range of market segments including pharmaceutical, biotech, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs approx. 485 people worldwide. The Group had sales of 1,092 MSEK in 2020 and our products are sold in more than 70 countries. Biotage's share (BIOT) is listed in the Mid Cap segment on the NASDAQ Stockholm.
Website: www.biotage.com
https://news.cision.com/biotage/r/new-capacity-helps-eliminate-bottleneck-for-covid-19-vaccines,c3396741
https://mb.cision.com/Main/705/3396741/1454298.pdf
(c) 2021 Cision. All rights reserved., source